ArticlePloS one2010
Novel siRNA delivery system to target podocytes in vivo.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Screening and Identification of Novel DNA Aptamer for Targeted Delivery to Injured Podocytes in Glomerular Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanomaterials for targeted therapy of kidney diseases: Strategies and advances.Materials today. Bio · 2025Review
- Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.Bioengineering (Basel, Switzerland) · 2024Review
- Physiological principles underlying the kidney targeting of renal nanomedicines.Nature reviews. Nephrology · 2024Review
- Application and design considerations of ROS-based nanomaterials in diabetic kidney disease.Frontiers in endocrinology · 2024Review
- Advanced Drug Delivery Systems for Renal Disorders.Gels (Basel, Switzerland) · 2023Review
- Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates.Journal of clinical medicine · 2021Review
- The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies.Advanced healthcare materials · 2017Review
- Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.Pediatric nephrology (Berlin, Germany) · 2016Review
- Drug discovery in focal and segmental glomerulosclerosis.Kidney international · 2016Review
- Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Pediatric nephrology (Berlin, Germany) · 2016Review
- Kidney-specific Sonoporation-mediated Gene Transfer.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown.Nature protocols · 2016Article
- Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Diabetes spectrum : a publication of the American Diabetes Association · 2015Article
- A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Diverse origins of the myofibroblast—implications for kidney fibrosis.Nature reviews. Nephrology · 2015Review
- siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA.Nucleic acid therapeutics · 2015Article
- Targeting Rapamycin to Podocytes Using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-Harnessed SAINT-Based Lipid Carrier System.PloS one · 2015Article
- Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing.Theranostics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Podocytes are injured in several glomerular diseases. To alter gene expression specifically in podocytes in vivo, we took advantage of their active endocytotic machinery and developed a method for the targeted delivery of small interfering ribonucleic acids (siRNA). We generated an anti-mouse podocyte antibody that binds to rat and mouse podocytes in vivo. The polyclonal IgG antibody was cleaved into monovalent fragments, while preserving the antigen recognition sites. One Neutravidin molecule was linked to each monovalent IgG via the available sulfohydryl group. Protamine, a polycationic nuclear protein and universal adaptor for anionic siRNA, was linked to the neutravidin via biotin. The delivery system was named shamporter (sheep anti mouse podocyte transporter). Injection of shamporter coupled with either nephrin siRNA or TRPC6 siRNA via tail vein into normal rats substantially reduced the protein levels of nephrin or TRPC6 respectively, measured by western blot analysis and immunostaining. The effect was target specific because other podocyte-specific genes remained unchanged. Shamporter + nephrin siRNA induced transient proteinuria in rats. Control rats injected with shamporter coupled to control-siRNA showed no changes. These results show for the first time that siRNA can be delivered efficiently and specifically to podocytes in vivo using an antibody-delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.